CymaBay Therapeutics, Inc. (CBAY) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Newark, CA, United States. वर्तमान CEO हैं Sujal A. Shah.
CBAY के पास है IPO तिथि 2014-02-03, 101 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $3.73B.
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and chronic metabolic diseases. The company's lead program, seladelpar (MBX-8025), a selective peroxisome proliferator-activated receptor delta agonist, is currently in Phase III clinical trials for primary biliary cholangitis (PBC) and has completed Phase 2b studies for nonalcoholic steatohepatitis (NASH). CymaBay is also advancing MBX-2982 in Phase 2a development for hypoglycemia management in type 1 diabetics. The company operates under licensing agreements with ABW Cyclops SPV LP for PBC development and maintains a worldwide license from Janssen Pharmaceuticals for research and commercialization of compounds targeting metabolic disease targets. Founded in 1988 as Metabolex, Inc. and headquartered in Newark, California, CymaBay is dedicated to addressing significant unmet medical needs in hepatic and metabolic disease treatment.
